Title Image

Press Releases


LSKB announces initiation of a US clinical trial studying the dose escalation and safety of apatinib mesylate (YN968D1) in solid tumor cancers


LSK BioPharma and Huntsman Cancer Institute Announce an Exclusive License Agreement for HCI-1401, a BTK inhibitor for treatment of B-cell malignancies and other diseases